Falnidamol
Falnidamol (BIBX 1382) is an orally active, selective EGFR tyrosine kinase inhibitor with an IC50 of 3 nM. Falnidamol displays > 1000-fold lower potency against ErbB2 (IC50=3.4 μM) and a range of other related tyrosine kinases (IC50>10 μM) . Falnidamol is a pyrimido-pyrimidine compound and has anti-cancer activity[1][2].
Product Specifications
CAS Number
196612-93-8
Product Name Alternative
BIBX 1382
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
EGFR
Type
Reference compound
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/BIBX-1382.html
Purity
99.41
Solubility
DMSO : 31.25 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
ClC1=CC(NC2=NC=NC3=CN=C(NC(CC4)CCN4C)N=C23)=CC=C1F
Molecular Formula
C18H19ClFN7
Molecular Weight
387.84
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
EGFR/ErbB1/HER1; ErbB2/HER2
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Renal Cell Carcinoma (Carbonic Anhydrase IX) (PN-15), CF640R conjugate, 0.1mg/mL
Cyclin E2 (CCNE2) (NM_057749) Human Over-expression Lysate
